PT  - JOURNAL ARTICLE
AU  - Gall, Laura Le
AU  - Duddy, William J
AU  - Martinat, Cecile
AU  - Mariot, Virginie
AU  - Connolly, Owen
AU  - Milla, Vanessa
AU  - Anakor, Ekene
AU  - Ouandaogo, Zamalou G
AU  - Millecamps, Stephanie
AU  - Lainé, Jeanne
AU  - Vijayakumar, Udaya Geetha
AU  - Knoblach, Susan
AU  - Raoul, Cedric
AU  - Lucas, Olivier
AU  - Loeffler, Jean Philippe
AU  - Bede, Peter
AU  - Behin, Anthony
AU  - Blasco, Helene
AU  - Bruneteau, Gaelle
AU  - Del Mar Amador, Maria
AU  - Devos, David
AU  - Henriques, Alexandre
AU  - Hesters, Adele
AU  - Lacomblez, Lucette
AU  - Laforet, Pascal
AU  - Langlet, Timothee
AU  - Leblanc, Pascal
AU  - Le Forestier, Nadine
AU  - Maisonobe, Thierry
AU  - Meininger, Vincent
AU  - Robelin, Laura
AU  - Salachas, Francois
AU  - Stojkovic, Tanya
AU  - Querin, Giorgia
AU  - Dumonceaux, Julie
AU  - Browne, Gillian Butler
AU  - González De Aguilar, Jose-Luis
AU  - Duguez, Stephanie
AU  - Pradat, Pierre Francois
TI  - Muscle cells of sporadic ALS patients secrete neurotoxic vesicles
AID  - 10.1101/2021.03.11.21252078
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.11.21252078
4099  - http://medrxiv.org/content/early/2021/03/12/2021.03.11.21252078.short
4100  - http://medrxiv.org/content/early/2021/03/12/2021.03.11.21252078.full
AB  - Background The cause of the motor neuron (MN) death that drives terminal pathology in Amyotrophic Lateral Sclerosis (ALS) remains unknown, and it is thought that the cellular environment of the MN may play a key role in MN survival. Several lines of evidence implicate vesicles in ALS, including that extracellular vesicles may carry toxic elements from astrocytes towards motor neurons, and that pathological proteins have been identified in circulating extracellular vesicles of sporadic ALS patients. Since MN degeneration at the neuromuscular junction is a feature of ALS, and muscle is a vesicle-secretory tissue, we hypothesized that muscle vesicles may be involved in ALS pathology.Methods Sporadic ALS patients were confirmed to be ALS according to El Escorial criteria, were genotyped to test for classic gene mutations associated with ALS, and physical function was assessed using the ALSFRS-R score. Muscle biopsies of either mildly affected deltoids of ALS patients (n=27) or deltoids of aged-matched healthy subjects (n=30) were used for extraction of muscle stem cells, to perform immunohistology, or for electron microscopy. Muscle stem cells were characterized by immunostaining, RTqPCR and transcriptomic analysis. Secreted muscle vesicles were characterized by proteomic analysis, Western blot, NanoSight, and electron microscopy. The effects of muscle vesicles isolated from the culture medium of ALS and healthy myotubes were tested on healthy human-derived iPSC motor neurons and on healthy human myotubes, with untreated cells used as controls.Results An accumulation of multivesicular bodies was observed in muscle biopsies of sporadic ALS patients by immunostaining and electron microscopy. Study of muscle biopsies and biopsy-derived denervation-naïve differentiated muscle stem cells (myotubes) revealed a consistent disease signature in ALS myotubes, including intracellular accumulation of exosome-like vesicles and disruption of RNA-processing. Compared to vesicles from healthy control myotubes, when administered to healthy motor neurons the vesicles of ALS myotubes induced shortened, less branched neurites, cell death, and disrupted localization of RNA and RNA-processing proteins. The RNA-processing protein FUS and a majority of its binding partners were present in ALS muscle vesicles, and toxicity was dependent on the expression level of FUS in recipient cells. Toxicity to recipient motor neurons was abolished by anti-CD63 immuno-blocking of vesicle uptake.Conclusion ALS muscle vesicles are shown to be toxic to motor neurons, which establishes the skeletal muscle as a potential source of vesicle-mediated toxicity in ALS.One Sentence Summary Muscle cells of ALS patients secrete vesicles that are toxic to motor neuronsCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was financed by Target-ALS (ViTAL consortium, PI: S Duguez), ARsLA (TEAM consortium, PI: S Duguez ; PULSE, PI: D Devos), European Union Regional Development Fund (ERDF) EU Sustainable Competitiveness Programme for N. Ireland, Northern Ireland Public Health Agency (HSC R&D) & Ulster University (PI : T Bjourson). LLG is a recipient from ArSLA. It was also partially supported by European Community's Health Seventh Framework Programme under grant agreement No. 259867 (Euro-MOTOR), INSERM, Sorbonne University, and the AFM. The study was sponsored by APHP. The authors declare that they have no conflict of interest. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Thirty deltoid muscle biopsies from healthy age and gender-matched subjects were obtained from the BTR (Bank of Tissues for Research, a partner in the EU network EuroBioBank) in accordance with European recommendations and French legislation. The protocols (NCT01984957) and (NCT02360891) were approved by the local Ethical Committee (Pitie Salpetriere, Paris) and all subjects signed an informed consent in accordance with institutional guidelines.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAssociated large-scale datasets (transcriptomic and proteomic) are uploaded to public repositories. Expression data were uploaded to the GEO repository at accession number GSE122261. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD015736. https://www.ncbi.nlm.nih.gov/geo/ https://www.ebi.ac.uk/pride/archive